Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leish-111f + MPL-SE Vaccine for Cutaneous Leishmaniasis
NCT00121862Phase 2Completed
- Sponsor
- Access to Advanced Health Institute
- Start
- Aug 2005
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Leish-111f + MPL-SE in cutaneous leishmaniasis (CL) (3 arms), sponsored by Access to Advanced Health Institute. Primary endpoints: Adverse events, Dose-limiting toxicities at Day 84 and 1 more. Started Aug 2005; status: completed.
02
Drugs
Leish-111f + MPL-SE
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT00121862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121862.